Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Vertex Pharmaceuticals Incorporated : Recent Studies from Vertex Pharmaceuticals Inc. Add New Data to Antiinfectives (Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2017 | 08:44pm CET

Recent Studies from Vertex Pharmaceuticals Inc. Add New Data to Antiinfectives (Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Drugs and Therapies - Antiinfectives have been published. According to news originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amide and urea substitutions on the pyrimidine-7-azaindole motif: In this work, we explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues."

Our news journalists obtained a quote from the research from Vertex Pharmaceuticals Inc., "Substitution at the 2-position of the azaindole ring generated somewhat less potent analogues, but reduced AO-mediated metabolism. Incorporation of a ring nitrogen generated 7-azaindazole analogues that were equipotent to the parent 2-H-7azaindole, but surprisingly, did not appear to improve AO-mediated metabolism. Overall, we identified multiple 2-substituted 7azaindole analogues with enhanced AO stability and we present data for one such compound (12) that demonstrate a favorable oral pharmacokinetic profile in rodents."

According to the news editors, the research concluded: "These analogues have the potential to be further developed as anti-influenza agents for the treatment of influenza."

For more information on this research see: Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza. ACS Medicinal Chemistry Letters, 2017;8(2):261-265. ACS Medicinal Chemistry Letters can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Medicinal Chemistry Letters - www.pubs.acs.org/journal/amclct)

The news correspondents report that additional information may be obtained from U.K. Bandarage, Vertex Pharmaceut Inc, Boston, MA 02210, United States. Additional authors for this research include M.P. Clarke, E. Perola, H. Gao, M.D. Jacobs, A. Tsai, J. Gillespie, J.M. Kennedy, F. Maltais, M.W. Ledeboer, I. Davies, W.X. Gu, R.A. Byrn, K.N. Addae, H. Bennett, J.R. Leeman, S.M. Jones, C. O'Brien, C. Memmott and Bennan (see also Drugs and Therapies - Antiinfectives).

Keywords for this news article include: Boston, Massachusetts, United States, North and Central America, Influenza, Epidemiology, Drugs and Therapies, Antiinfectives, Antivirals, Vertex Pharmaceuticals Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
03/23 VERTEX PHARMACEUTICALS INCORPORATED : Recent Studies from Vertex Pharmaceuticals..
03/23 VERTEX PHARMACEUTICALS INCORPORATED : Findings from Vertex Pharmaceuticals Inc. ..
03/16 CONCERT PHARMACEUTICALS : Vertex to Acquire CTP-656 from Concert Pharmaceuticals..
03/09 VERTEX PHARMACEUTICALS INCORPORATED : to Present at the Cowen Healthcare Confere..
03/07 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Entry into a Material ..
03/06 VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement, Fi..
03/06 VERTEX PHARMACEUTICALS INCORPORATED : to Acquire CTP-656 from Concert Pharmaceut..
03/02 VERTEX PHARMACEUTICALS INCORPORATED : to Present at the Cowen Healthcare Confere..
02/24 VERTEX PHARMACEUTICALS INCORPORATED : Reports Summarize Gastroenterology Study R..
02/23 VERTEX PHARMACEUTICALS INCORPORATED : INC / MA MANAGEMENT'S DISCUSSION AND ANALY..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09:00a A REVIEW OF CONCERT'S FILED PRE 14A : The CTP-656 Saga May Not Be Done Yet
03/17 Vertex Pharma upgraded at JMP
03/13 Assessing Jon Meacham's Open Letter To Gilead
03/09 Premarket analyst action - healthcare
03/08 Gilead And Merck Should Take Drastic Action On Acquisitions As Hepatitis C Dr..
Advertisement
Financials ($)
Sales 2017 2 035 M
EBIT 2017 409 M
Net income 2017 124 M
Finance 2017 680 M
Yield 2017 -
P/E ratio 2017 135,01
P/E ratio 2018 43,69
EV / Sales 2017 10,5x
EV / Sales 2018 8,20x
Capitalization 22 123 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 100 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..20.88%22 123
AMGEN, INC.13.56%122 281
CELGENE CORPORATION6.45%95 861
GILEAD SCIENCES, INC.-5.75%88 214
REGENERON PHARMACEUTIC..-0.56%38 722
ACTELION LTD24.72%29 697
More Results